Cardiopulmonary Changes Following Spinal Cord Stimulation in Individuals With Spinal Cord Injury

NANot yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2028

Conditions
Spinal Cord InjuriesCardiovascular DiseasesCardiopulmonary Diseases
Interventions
DEVICE

Transcutaneous Spinal Cord Stimulation (tSCS)

Transcutaneous spinal cord stimulation (tSCS) will be delivered via a non-invasive central nervous system stimulator TESCoN or SCONE (SpineX Inc., CA - experimental type II medical devices) through self-adhesive electrode(s) placed on the skin between spinous processes over the midline of the vertebral column as the cathode(s) and two rectangular electrodes placed symmetrically on the skin over the iliac crests as anodes. Stimulation will be applied at various waveforms and frequencies (ranging between 1Hz and 90Hz) with and without a carrier frequency. Current amplitude will start at 10mA and proceed incrementally until tolerable or responses plateau. If spasticity occurs or is uncomfortable, the current will be decreased. Specific areas for electrode placement will be examined and prepared to reduce skin impedance. tSCS will be delivered under the supervision of a physician (Dr. Krassioukov/Dr. Berger) by trained doctoral/post-doctoral trainees.

Trial Locations (1)

V5Z 1M9

Blusson Spinal Cord Centre, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER